Skip to content

Observational study about the association between ovarian cancer recurrence prevention and parameter of immunity with the deep-ocean water

Observational study about the association between ovarian cancer recurrence prevention and parameter of immunity with the deep-ocean water - Observational study about the association between ovarian cancer recurrence prevention and parameter of immunity with the deep-ocean water

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025715
Enrollment
20
Registered
2017-01-17
Start date
2015-03-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

A group (the DOW administrated group): I drink Depp Ocean Water(DOW) 500 ml/day in normal life. I perform a study from a registration start with a period to being finished. B group (control group): I

Sponsors

Kochi Medical School
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: We I choose the patient who does not have an exclusion item among the ovarian cancer patients whom the 80-year-old first induction of remission was got from from 50 years old that received the hospital obstetrics and gynecology department attached to the Kochi University medical department.

Exclusion criteria

Exclusion criteria: 1.Person (immunosuppressive drug, adrenal cortical hormone) who takes the drug which may influence the endpoint 2.The person who needs water restrictions due to the disease including heart failure, the renal insufficiency 3.The person who participates in other clinical trials 4.One having serious complications including renal insufficiency, liver failure, the heart failure 5.One having the high blood pressure that is not controlled by medical treatment 6.One having lower limbs vein thrombosis 7.One having lower limbs lymphedema

Design outcomes

Primary

MeasureTime frame
Parameter (CD3.CD4.CD8.CD12.CD11b.CD19.CD16.CD56) of the host of immunity

Secondary

MeasureTime frame
PFS OS

Countries

Japan

Contacts

Public ContactTakashi Ushiwaka

Kochi Medical School Obstetrics and gynecology

takashi-u@kochi-u.ac.jp088-880-2383

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026